Herein, we demonstrated that GSK484, a reversible inhibitor of PAD4 (39), significantly reduced thrombus formation in 4T1 tumor-bearing mice, although to a lesser extent than DNase I. Overall, it remains to be determined whether preventing the formation of NETs or degrading NETs could efficiently prevent cancer-associated thrombosis in human patients. Here, PADI4 is linked to cancer.